ClinicalTrials.gov
ClinicalTrials.gov Menu

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (UW PIC 330)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00781287
Recruitment Status : Terminated (Enrollment too slow.)
First Posted : October 28, 2008
Last Update Posted : August 12, 2013
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Ann Collier, University of Washington

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study will test the hypothesis that use of the integrase inhibitor raltegravir (400 mg BID orally) to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+ T-cells to a greater extent than a 3-drug HAART regimen.

Condition or disease Intervention/treatment Phase
Human Immunodeficiency Virus Drug: 3-drug anti-HIV therapy Drug: Raltegravir Phase 4

Detailed Description:
The study will be conducted at the UW Primary Infection Clinic and the UW AIDS Clinical Trials Unit. Secondary objectives will characterize safety, tolerability, plasma HIV-1 RNA and CD4+ T-cell values. The 3-drug HAART will be chosen and provided by the subject.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir
Study Start Date : February 2009
Actual Primary Completion Date : February 2012
Estimated Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Raltegravir + 3-drug anti-HIV therapy Drug: 3-drug anti-HIV therapy
3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)

Drug: Raltegravir
400 mg BID PO
Other Name: Isentress
Active Comparator: 3-drug anti-HIV therapy Drug: 3-drug anti-HIV therapy
3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of HIV-1 infected CD4+ T-cells measured by a quantitative HIV-1 DNA PCR assay [ Time Frame: 96 weeks ]

Secondary Outcome Measures :
  1. CD4+ T-cells [ Time Frame: 96 weeks ]
  2. Plasma HIV-1 RNA [ Time Frame: 96 weeks ]
  3. Grade 3 and 4 signs and symptoms or laboratory toxicities at least one grade higher than baseline [ Time Frame: From study drug start to 8 weeks after drug discontinuation ]
  4. Plasma HIV-1 RNA [ Time Frame: Baseline to Week 8 ]
  5. Tolerability (Discontinuation of raltegravir) [ Time Frame: 96 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute or Early HIV-1 infection
  • HIV-1 RNA > or equal to 500 copies/mL
  • Acceptable safety lab results (specified in protocol)
  • Negative pregnancy test for females
  • Willingness to use contraception (for females of reproductive potential

Exclusion Criteria:

  • Prior receipt of investigational HIV-1 vaccine
  • Use of immunomodulators other than systemic steroids within 30 days before entry
  • Serious medical or psychiatric illness that would interfere with study participation
  • Active drug or alcohol use that would interfere with study participation
  • Allergy/hypersensitivity to raltegravir
  • Pre- or Post-exposure prophylaxis for the exposure that led to HIV-1 acquisition
  • Pregnancy or breastfeeding
  • History of malignancy (other than localized squamous cell or basal cell cancer of the skin)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00781287


Locations
United States, Washington
University of Washington Primary Infection Clinic
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Ann C. Collier, MD University of Washington
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
University of Washington Primary Infection Clinic web site  This link exits the ClinicalTrials.gov site

Responsible Party: Ann Collier, Professor of Medicine, University of Washington
ClinicalTrials.gov Identifier: NCT00781287     History of Changes
Other Study ID Numbers: 34908-D
First Posted: October 28, 2008    Key Record Dates
Last Update Posted: August 12, 2013
Last Verified: August 2013

Keywords provided by Ann Collier, University of Washington:
human immunodeficiency virus
raltegravir
primary HIV infection
HIV-1

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
 Slow Virus Diseases
Raltegravir Potassium
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action